Introduction
Apoptosis plays roles in both organ development and tissue homeostasis. Its deregulation, together with defective control of proliferation, contributes to critical tumor progression (Evan and Vousden, 2001; Steinbach et al., 2002; Debatin et al., 2003) . Analyses of cell turnover relating to apoptosis and proliferation provide insights into tumor doubling time, prognosis and treatment response (Zhang et al., 1998) in that high apoptotic counts have been associated with a high histological grade and shortened survival in a number of studies (Vakkala et al., 1999) . This cell death program is known to be activated or inactivated by a variety of genes, such as Bcl-2 and Bcl-xL, Bak and Bax.
Especially, members of the Bcl-2 gene family play critical roles in apoptotic regulation in cancer cells, not only in tumorigenesis, but also in chemotherapyinduced cell death (Reed, 1995) .
The proapoptotic Bcl-2 family can be separated into two subgroups. The first subgroup includes members of multiple Bcl-2 homology (BH) domain proteins, such as Bax; these gene proteins contain several BH regions. The second subgroup includes proteins that share only the homologous BH3 domain, an amphipathic a-helical segment that is necessary for triggering cell death (Chittenden et al., 1995) . The BH3 domain inactivates apoptosis, but apparently does not interact with the proapoptoic proteins, Bak or Bax (Inohara et al., 1997) . Members of this newly described group of BH3-only proteins-including HRK/DP5, Bim, Noxa, Bbc3/ Puma, Bmf, Bad, Bik/Blk/Nbk and Bid-all share the biological function of promoting Bax-dependent apoptosis through mitochondrial release of cytochrome c and initiation of downstream cell death programs (Puthalakath and Strasser, 2002) . Among these factors, a novel regulator of cell death, Human Hrk, and its mouse homolog (DP5) (Imaizumi et al., 1997) , regulates Bcl-2 and Bcl-xL through selective interaction with the BH3 domain (Inohara et al., 1997) .
HRK, discovered by Inohara et al. (1997) , was itself originally identified as a proapoptotic gene located at 12q13.1 and is transcriptionally regulated in various cell types (Imaizumi et al., 1999; Sanz et al., 2000) , being induced within an hour after administration of cell death stimuli (Harris and Johnson, 2001) . HRK also selectively interacts with survival-promoting proteins, Bcl-2 and Bcl-xL. Common to the BH3 proteins, the product of HRK localizes to the membranes of intracellular organelles in a pattern similar to that reported earlier for Bcl-2 and Bcl-xL. HRK is prevalently expressed in hematopoietic tissues and cultured neurons (Inohara et al., 1997; Sanz et al., 2000) , but has also been shown in the pancreas, liver, lung, kidney and prostate (Inohara et al., 1997; Higuchi et al., 2008) . The role of HRK in apoptosis has been described mainly in hematopoietic tissues and cultured neurons; transcription of HRK is specifically induced at the mRNA and protein levels after growth factor withdrawal in these cells, leading to cell death (Sanz et al., 2000; Harris and Johnson, 2001) . Levels of HRK are high in embryonic neuronal tissues that undergo apoptosis (Imaizumi et al., 1997) , and in cultured neurons, its expression is increased after nerve growth factor withdrawal or exposure to b-amyloid (Imaizumi et al., 1999) .
Interestingly, b-amyloid-induced apoptosis of cultured neurons was shown to be mediated by E2F1 (Giovanni et al., 2000) .
Some studies have also shown that transcription of the HRK gene is under the control of the c-Jun N-terminal kinase pathway (Harris and Johnson, 2001) as well as the transcriptional repressor DREAM (Sanz et al., 2002) and that apoptosis by HRK requires the expression of Bax (Harris and Johnson, 2001 ). Sunayama et al. (2004) have shown that HRK appears to be located in the mitochondria associated with p32. This suggests that physical and functional interaction with p32 could have a crucial role in HRK-mediated apoptosis. In addition, the overexpression of Bcl-2 or Bcl-xL inhibits the induction of HRK and prevents apoptosis after growth factor withdrawal (Sanz et al., 2000) . As enforced coexpression of HRK and the antiapoptotic protein, Bcl-2 or Bcl-xL, inhibits the death-promoting activity of HRK (Inohara et al., 1997) , it appears that the balance between the steadystate levels of Bcl-xL or Bcl-2 and those of HRK either suppresses or induces apoptosis.
The expression of HRK in hematopoietic progenitor cell lines can be induced not only by growth factor withdrawal but also by treatment with etoposide, a chemotherapeutic drug that induces apoptosis. On growth factor withdrawal or treatment with certain chemotherapeutic drugs, the repressor mechanism may be released (that is, by post-translational modification or binding to a specific factor), allowing the expression of HRK. Thus, alterations in protein form/expression may also be a critical feature for the survival or cell death of cancer cells, enabling them to escape apoptosis resulting from the DNA damage caused by chemotherapeutic drugs and/or radiotherapy (Zhang et al., 2000) . The loss of HRK expression and the underlying mechanism(s) of downregulation, however, have not been widely examined in human malignancies.
In this text, we reviewed the 5 0 -CpG methylation status, loss of heterozygosity (LOH) on 12q13.1 and its association with HRK expression in human malignancies, including prostate cancer, astrocytic tumor and primary central nervous system lymphoma.
HRK alteration in human malignancies

Prostate cancer
In western countries, prostate cancer is the most common malignancy and the second leading cause of cancer death in men (Nelson et al., 2003) . Various studies have been performed investigating the genetic factors related to prostate carcinogenesis (Konishi et al., 2005a (Konishi et al., , b, 2008 , but as yet, critical specific molecular markers that clearly identify malignant potential have not been found. Apoptosis regulators play one of the most critical roles in tumorigenesis, and an imbalance between cell proliferation and apoptosis contributes to tumor progression (Steinbach et al., 2002; Debatin et al., 2003) . Analyses of apoptosis and proliferation provide much clinically useful information for tumor development, prognosis and treatment response (Nakamura et al., 1997) . Some limited studies have focused on critical regulators of apoptosis (Steinbach et al., 2002; Debatin et al., 2003) , and high apoptotic counts have been associated with high histological grade and shortened survival . Activated regulation of mitogen-activated protein kinases and Fas-associated death domain-containing proteins affects cell growth, proliferation, survival and progression in prostate cancers . HRK seems to be an important component in the regulation of apoptosis on tumor cells and the inactivation of HRK, leading to loss of HRK expression and subsequent low apoptotic counts-events that may be relevant to the pathogenesis of prostate cancer.
Aberrant methylation of HRK in the gene promoter and exon 1. DNA methylation patterns in the promoter region can be determined by methylation-specific PCR (Herman et al., 1996) . In addition to that of many tumor suppressor genes, transcription of HRK might be regulated by the promoter that is rich in CpG dinucleotides. The question, however, arises as to whether or not a reduced HRK expression in the tumor samples can be explained solely by promoter methylation of the gene. CpG islands of HRK are relatively large, and it is not clear whether they are coordinately regulated with respect to hypermethylation. To address the issue, we originally designed methylated and unmethylated methylation-specific PCR primers that spanned the transcription start site and translation start site for both promoter and exon 1 sequence Higuchi et al., 2008) . Methylation of the HRK promoter was detected in 0, 14, 38, 100 and 25% of cancers graded as Gleason score (GS), respectively (Table 1 and Figure 1 ). Detectable exon 1 methylation was marginally more frequent in lowergrade lesions; however, methylation of exon 1 occurred at the same frequency as promoter methylation in higher-grade cancers. In comparison, none of the 30 samples of normal epithelial or stromal tissues from areas adjacent to the tumors showed methylation in either gene region probed.
Detection of HRK mRNA by reverse transcription PCR and immunohistochemistry. Although transcripts for HRK were retrieved in the majority of normal controls and lower-grade prostate cancers, PCR products corresponding to HRK were less infrequently found in highgrade cancers (Table 1 and Figure 1 ). Cytoplasmic expression of HRK by immunohistochemistry was observed in epithelial cells in peritumoral prostate tissues (Figure 2 ). Among tumor tissues, 88% of lesions with GS 5 and 6 were immunopositive for HRK, with more than 20% of cells counted showing staining. In contrast, higher-grade lesions tended to show less HRK expression overall (Table 1 ). There was significant positive correlation between HRK transcription and HRK immunoreactivity, specifically in GS 6 tumors in that a majority of lesions showed transcripts in both analyses.
HRK expression was readily detectable in GS 5 and 6 cancers without apparent HRK methylation. In contrast, the expression of HRK was not detected in highergrade cancers that showed methylation in both regions of exon 1 and promoter (Table 1) . Abnormal methylation may be a specific feature of HRK in various tumor cells that is not found in any other member of the BH3 family (Obata et al., 2003) . Expression of HRK is regulated at the transcriptional level by cellular stress apparently caused by the absence of growth factors (Sanz et al., 2000) , whereas protein expression of other BH3 family members is regulated by post-transcriptional mechanisms (Inohara et al., 1997) . For example, although HRK activity is mediated by its methylation status at the transcription start site of the gene, the proapoptotic activity of BAD is controlled by the level of its phosphorylation (Downward, 1999) .
HRK methylation and expression and 12q13.1 LOH. Could reduced HRK expression be determined solely by methylation at the transcription start site of the gene? Figure 1 (a) Results of methylation-specific PCR of CpG islands of the HRK promoters in prostate cancers. In case 1, who assigned a Gleason score of 6 (GS 6), methylation occurred in exon 1 of HRK, rather than in the promoter region. Cases 6 (GS 8), 7 and 8 (GS 7), however, were HRK methylated in both promoter and exon 1 (U, PCR product amplified by unmethylation-specific primers; M, PCR product amplified by methylation-specific primers; NC, negative control; PC, positive control). (b and c) RT-PCR analysis of HRK mRNA expression in prostate cancer. HRK expression was evident in cases 3 (GS 5), 4, 9 (both GS 6), 10 and 11 (both GS 7) despite apparent lack of 12q13.1 LOH. However, both of this were positive for both LOH and HRK promoter and exon 1 methylation in case 8 (N, normal control). This figure is modified from Higuchi et al. (2008) . RT-PCR, reverse transcription PCR. Another possibility is that, in some samples, only one allele of the HRK gene is hypermethylated. In these cases, the specific methylated and unmethylated bands would be expected to be of equal intensity. The HRK gene is located in 12q13.1, where LOH has frequently been detected in human tumors (Kim et al., 2001; Wistuba et al., 2001) ; thus, HRK may be inactivated not only by DNA methylation, but also by gene deletion. A significant relationship between 12q13.1 LOH and repression of both HRK mRNA and protein levels has been shown, although LOH at 12q13.1 was detected in only 23% of the prostate cancers analysed (Table 1 ). In the cohort of GS 6 cancers, two of four cases showing LOH also showed methylation of both the promoter and exon 1 of the gene. In contrast, all seven GS 7 cancers showing allelic loss in this region exhibited concurrent gene methylation in both regions. However, two cases with LOH still yielded detectable HRK expression. Therefore, LOH alone may not completely suppress HRK expression because many genes can be expressed in a monoallelic fashion. Some DNA methylation-independent mechanisms, including mutations or loss of one or more allele, may also be assumed.
Apoptotic indices. When evaluating the apoptotic cell number, we confirmed the presence of standard morphological characteristics of apoptosis. Moreover, we employed the transferase-mediated digoxigenin-tagged 16-desoxy-uridine-triphosphate nick end-labeling (TU-NEL) assay to detect and quantify apoptosis in the tumor specimens. Only those cells showing darkly stained nuclei or nuclear fragments with a cytoplasmic halo were recognized as TUNEL-positive apoptotic cells. A significant difference in the incidence of prostate epithelial cell apoptosis was detected between tumors with a GS of 5-6 and those with a GS of 7 or higher (Table 1) . We have also shown a close inverse correlation between loss of HRK expression by immunohistochemistry and decreased apoptotic indices (AIs) in cancers of each grade. The association between apoptosis and HRK inactivation was uncovered, indicating that both genetic hypermethylation and allelic loss of apoptotic-associated genes can contribute to aberration of apoptotic regulation in prostate cancer.
Detection of multiple methylated genes and p53 mutations. It is noteworthy that prostate cancer exhibiting HRK methylation tends to show methylation in the panel of genes. Co-methylation of HRK and p14 ARF occurred in 13% of evaluated lesions; 47% showed methylation of both HRK and p16
INK4a ; O 6 -MGMT and HRK were methylated in 60% of samples; and comethylation of GST-P and HRK was detected in 87% of informative lesions. Prostate carcinomas could be grouped with other cancers displaying CpG island methylator phenotype (CIMP). CIMP was initially described in colorectal cancers, and tumors exhibiting CIMP have a global promoter hypermethylation pattern that contributes to tumorigenesis (Toyota et al., 1999) . It remains unclear why HRK and one or more of these specific apoptosis-related genes are more likely to undergo structural alterations, but genetic instability might be closely associated with multiple epigenetic effects, such as methylation, which occur during the course of tumor progression. In colorectal cancers, cases without p53 mutations have frequently shown aberrant methylation of HRK (Obata et al., 2003) . Mutation of p53 was detected in a low number of GS 6 and 7 cancers (9 and 13%, respectively), but not in other tumors with higher GS. p53 mutations and p14 ARF methylations or deletions are rare in both GS 6 and 7 cancers, a finding that leads us to believe that aberrations in the p14 ARF /p53/HRK apoptotic pathway are not necessarily related to prostate tumorigenesis. It has also been shown that reduced phosphorylation of Fas-associated death domain-containing protein is associated with progression in high-grade prostate cancer (Shimada et al., 2005) . A GS of 7 is thought to be a borderline score for a good prognosis in prostate cancers Shimada et al., 2006) ; perhaps significantly linked HRK inactivation and decreased AIs were detected in cancer samples graded GS 7. Therefore, assays based on evaluating a combination of genetic alterations, including HRK hypermethylation, LOH, dephosphorylation and mutation, might be useful in the prognosis of prostate cancers.
Astrocytic tumors
High-grade astrocytic tumors, especially glioblastoma (WHO grade IV), are the most frequent and most malignant tumors of the human nervous system. From a clinical and biological point of view, glioblastomas are divided into two subtypes: primary or de novo glioblastomas develop rapidly, without clinical or histopathological evidence of less-malignant precursor lesions, and constitute the majority of diagnosed cases, whereas secondary glioblastoma develops more slowly and progressively from low-grade diffuse (WHO grade II) or anaplastic (WHO grade III) astrocytoma (Kleihues et al., 2002) . Glioblastomas typically are very resistant to induction of apoptosis and, consequently, do not respond well to conventional chemotherapy. HRK is reportedly an important proapoptotic in cultured neurons and is repressed by the expression of deathrepressor proteins (Inohara et al., 1997; Sanz et al., 2000) . However, there have been no reports on the expression and/or the actual role of HRK distinctive from astrocytic tumor.
Aberrant methylation of HRK. In our series of astrocytic tumors, methylation of the HRK promoter was observed in 19% (7/36) of low-grade diffuse astrocytomas, in 22% (7/32) of anaplastic astrocytomas, in 27% (17/64) of primary glioblastomas and in 43% (12/28) of secondary glioblastomas (Table 2) , whereas 25, 25, 31 and 50% of these individual subtypes, respectively, showed exon 1 methylation. Neither the promoter nor exon 1 was methylated in normal cells from areas adjacent to the tumors.
Detection of HRK expression. Both membrane and cytoplasmic immunoreactivity to HRK were detected in peritumoral neurons and glial cells in the brain tissue specimens. There was a significant increase in the frequency of loss of HRK expression in secondary glioblastomas compared with other types of tumors; more than half of the secondary glioblastoma cases showed little to no immunohistochemical response. In contrast, HRK immunoreactivity was consistently higher in the other tumor subtypes in that 86% of diffuse astrocytomas, 78% of anaplastic astrocytomas and 72% of primary glioblastomas showed HRK expression in more than 20% of cells (Table 2 and Figure 2 ). This reflects a clear trend toward decreasing level of HRK expression with increasing tumor grade. mRNA transcripts were retrieved in the majority of normal controls, but 18% of diffuse astrocytomas, 30% of both primary glioblastomas and anaplastic astrocytomas and 57% of secondary glioblastomas yielded no detectable reverse transcription PCR products corresponding to HRK. This loss of HRK mRNA transcription significantly correlated with HRK immunoreactivity in each category of tumor.
Reduced or lost HRK expression was significantly associated with CpG island methylation in the promoter region in each type of astrocytic tumor. However, some few tumors showed exon 1 methylation, yet retained HRK expression. This suggests that methylation of the first exon is only partially related to gene expression in astrocytic tumors at least, whereas methylation of the promoter region correlated more significantly with gene expression. Thus, our data have first suggested that the aberrant methylation of HRK is associated with loss of protein and mRNA expression, and is probably the main mechanism of transcriptional silencing of HRK in astrocytic tumors. A clear agreement between decreased mRNA level and reduced HRK expression also indicates that HRK expression very likely stems from an altered transcription of the gene. This could be mediated by the difference in high-grade tumor heterogeneity, in which one region is methylated, the other regions being unmethylated and expressing the gene. Hypermethylation of HRK appeared to become more frequent as the lesion progressed as this epigenetic alteration was significantly more frequent in secondary glioblastomas than in other types of tumors analysed. In addition, if hypermethylation was detected in earlier lesions, it was usually also observed in the corresponding secondary glioblastoma.
Correlation of expression and LOH at 12q13.1 with HRK methylation status. There were significant relationships between 12q13.1 LOH and repression of both HRK protein and mRNA. Twenty-five samples lacking HRK expression, but exhibiting aberrant methylation and LOH, suggest that the biallelic inactivation of the gene resulted from the loss of one allele and 5 0 -CpG methylation in the remaining allele. Of the 38 astrocytic tumors detected with 12q13.1 LOH, six tumors showed low expression of mRNA and protein without promoter hypermethylation. In these cases, the HRK gene might have been silenced by another genetic or epigenetic mechanism, such as specific mutations or histone deacetylation. There were few other tumors with no demonstrable HRK expression and no evidence of 5 0 -CpG methylation and LOH. Alternatively, negative expression could result from several pathways of gene inactivation, such as loss of transcription factors or dysfunction of the regulatory proteins.
Evaluation of AI. Higher apoptotic counts in situ have been strongly associated with a higher histological grade. A pattern of HRK expression was indicated specific to secondary glioblastoma and correlated with the incidence of apoptosis. The mean AI in those secondary glioblastomas with hypermethylated promoter sequences was also significantly lower than in those without promoter methylation, but the AI showed no correlation with HRK expression and hypermethylation in the other subtypes of tumors. The diversity of mechanisms involved in the regulation and implementation of programmed cell death, which is indicative of the rich variety of targets for inhibition of apoptosis during tumorigenic development, must be considered.
Association with other genes. Similar to colorectal cancers (Obata et al., 2003) , methylation of the gene was more frequently detected in p53-competent secondary glioblastomas than in those with p53 mutations. This significant inverse association strongly suggests that HRK and p53 act within the same pathway. Epigenetic inactivation of HRK may thus lead to loss of apoptosis in secondary glioblastomas still expressing wild-type p53.
HRK methylation was detected exclusively in tumors showing a simultaneous methylation of multiple genes, that is p14 ARF and p16
INK4a
. The astrocytic tumors included in our series may also belong to the CIMP group and have downregulation of these genes through aberrant 5 0 -CpG methylation (Toyota et al., 1999) . Noting the relation between INK4a/ARF gene alteration, as well as high frequencies of the p53 mutation, and LOH with HRK inactivation, we believe that structural genetic alterations involved in the 'p14 ARF -p53-HRK' apoptosis pathway are likely to be present in secondary glioblastomas. Although it remains unclear why HRK and p16
INK4a and p14 ARF are prone to undergo such structural alterations, genetic instability might be closely associated with one or more particular regions in such cancer-linked genes, especially in secondary glioblastoma Ehrlich, 2002) . It is also noteworthy that a majority of genes reported to be methylated in tumors also tend to be methylated in regions associated with lower-grade malignancy (Toyota et al., 1999; Nakamura et al., 2001a Nakamura et al., , b, 2005a . In agreement with these reports, HRK methylation was detected less frequently in low-grade diffuse astrocytoma, suggesting that inactivation of the gene may be involved in a critical step in malignant progression.
Primary central nervous system lymphoma Primary central nervous system lymphoma (PCNSL) is defined as a diffuse lymphoma presenting in the brain or spinal cord in the absence of systemic lymphoma. There are no lymph nodes or lymphatics within the nervous system and, therefore, the pathogenesis of PCNSL in immunocompetent patients is still poorly understood. Apoptosis regulators play one of the most critical roles in tumorigenesis in many tissues, including malignant lymphomas (Debatin et al., 2003) . HRK, which was itself originally identified as a proapoptotic gene, was induced by diminished levels of cytokine in hematopoietic cells and cultured neurons and repressed by the expression of death-repressor proteins (Inohara et al., 1997; Sanz et al., 2000) . Transcription of HRK is specifically induced after growth factor withdrawal in hematopoietic tissues (Inohara et al., 1997) .
Methylation status of HRK vs HRK expression and LOH at 12q13.1. Methylation of the HRK promoter and of exon 1 was detected in 10 cases in 35 PCNSLs (Table 3) , but in none of the normal cells from areas adjacent to the tumors. The concurrent methylation of both the promoter region and exon 1 occurred in six cases. Hypermethylation and loss of HRK expression appeared to become more frequent as the lesions progressed. In two patients with recurring tumors, if hypermethylation and HRK loss were detected in earlier lesions, it was also observed in later lesions. In addition, we saw HRK promoter methylation in three recurrent tumors in which the primary lesions were unmethylated, suggesting that HRK methylation may occur in latter stages of PCNSL tumorigenesis or may be related to recurrence/malignancy.
Immunohistochemically, 29% of PCNSLs showed a loss of expression, whereas the remaining cases all showed immunoreactivity in more than 20% of cells. The reduction in gene expression revealed by the immunohistochemical analysis correlated highly with the amount of mRNA transcript, which was further confirmed by the reverse transcription PCR analysis. There was a clear correlation between aberrant promoter methylation and silencing of HRK as in similar prostate cancer or astrocytic tumors. We showed a significant association between reduced HRK expression and promoter hypermethylation; however, some cases showing exon 1 methylation were also positive for HRK expression. This indicates that the promoter region, including the upstream transcription-starting site, may strongly regulate HRK expression and relate to biological significance in PCNSLs, but it may not be the only important target for methylation in all tumors.
When compared with LOH at the gene locus, a significant positive association was found between concurrent promoter methylation/LOH and repression of both HRK mRNA and protein levels (Table 3) . A total of five cases without HRK expression showed both methylation and LOH, whereas all 19 tumors with expressing HRK showed an unmethylated promoter region and retention of both alleles at 12q13.1. Biallelic inactivation of the gene potentially resulted from the loss of one allele and methylation of the other. It should also be pointed out that two cases with LOH still showed detectable HRK expression. As many genes can be expressed monoallelically, LOH alone may not completely suppress HRK expression. Another possibility is that HRK expression is dependent on the presence of several distinct tumor sub-populations, one of which might have lost the expression due to methylation, whereas others remained unmethylated and protein expressive. Alternatively, partial methylation at only some sites or methylation of only one allele in these tumors may result in the positive mRNA/protein expression observed. In the same vein, we saw a clear correlation between methylation þ LOH and silencing of HRK in all samples except for 2 cases; in these tumors, HRK expression was lost despite the lack of gene methylation and LOH.
Correlation with apoptosis and therapy. Overall, the mean AI of cases was 2.83±2.06%. There was a close correlation between the loss of HRK expression and a decreased AI. In addition, the mean AI of methylated tumors was significantly lower than that of unmethylated lesions, suggesting the involvement of HRK apoptosis pathway.
As described in the section of astrocytic tumors, an inverse correlation was found between the methylation of the HRK gene and p53 mutations in secondary glioblastomas, suggesting the involvement of structural genetic alterations in the 'p14 ARF /p53/HRK' apoptosis pathway. Our analysis of PCNSLs failed to corroborate that hypothesis. However, we did detect a p53 mutation in a single tumor sample, indicating that p53 cannot be ruled out in the development of some PCNSLs. It has also been reported that tumors expressing wild-type p53 tend to be resistant to gene therapy using adenovirusmediated transfer of the p53 gene (Sasaki et al., 2001) . Epigenetic therapies using 5 0 -aza-2 0 -deoxycytidine may represent a useful alternative strategy for treating such cases, although further studies are required to determine whether cells expressing HRK are susceptible to apoptosis induced through chemotherapeutic drugactivated pathways.
Methylation status of HRK and other genes. HRK methylation was detected exclusively in our series of PCNSLs showing simultaneous methylation of multiple genes (p14
INK4a , RB1, O 6 -MGMT and p27
Kip1
) as well as prostate cancers and astrocytic tumors. Ten cases showed methylation in more than three genes, and among those, 80% cases showed HRK methylation, whereas only 3 of the 21 cases showing methylation in less than two genes, did so. It remains unclear why HRK and one or more of these specific genes are more likely to undergo structural alterations, but genetic instability might be closely associated with multiple epigenetic effects, including methylation, that occur during the course of tumor progression.
Patient outcome. Mean overall survival for patients with methylated HRK was not significantly different from that for those patients whose primary tumors did not show HRK methylation, whereas the relapse-free survival time in patients having HRK methylationpositive tumors was significantly shorter than that for those whose tumors were HRK methylation-negative (Figure 3 , P ¼ 0.028, log-rank test). In a number of instances, the presence of CIMP in a tumor has been correlated with clinicopathological features and/or prognosis (Toyota et al., 1999; Esteller et al., 2001) . In our investigation, we found that methylation of multiple genes (>3 genes) in PCNSLs was an independent and strong predictor of disease-specific recurrence and survival ( Figure 3 ). Epigenetic tumor profiling by methylation status might be a more powerful biomarker of risk prediction in PCNSLs than are other clinicopathological features and may reflect the silencing of critical genes affecting growth control, proliferation, apoptosis and cell differentiation that can lead to selective growth advantage, tumor progression, recurrence and decreased survival.
Conclusions
Aberrant methylation of CpG islands within the promoter is an epigenetic event largely responsible for silencing of the HRK gene and subsequent low apoptotic counts in our series of malignancies, including prostate cancer, astrocytic tumors and PCNSL, particularly when coupled with alleleic LOH. Inactivation of HRK in combination with the methylation profile of other multiple genes apparently occurs in a substantial proportion of all tumor phenotypes and, as a potential proapoptotic gene, may contribute to the development and progression of these tumors. It is also noteworthy that PCNSLs exhibiting CIMP have a significant correlation with shorter progression-free survival and overall survival. In addition, we provide some evidence that HRK may be involved in the progression from low-grade astrocytoma to secondary glioblastoma, but does not play a major role in the evolution of primary glioblastoma. Figure 3 (a and b) Kaplan-Meier curves reflecting the probability for 35 patients of having no recurrence with PCNSL in relation to the methylation status. A statistically significant difference in recurrence rate was observed between the promoter methylation-positive and promoter methylation-negative groups. There is no statistical difference for overall survival in relation to the methylation status. HRK-M ( þ ), methylated HRK group; HRK-M (À), unmethylated HRK group. (c and d) Kaplan-Meier curves for relapse-free survival (c) and overall survival (d) in relation to the methylation status of all 35 patients with PCNSL. 3M ( þ ), methylated more than three genes group; 3M (À), methylated less than three genes group. This figure is modified from Nakamura et al. (2006) . PCNSL, primary central nervous system lymphoma.
